Lyra Therapeutics Q1 EPS $(0.35) Misses $(0.26) Estimate, Sales $532.00K Beat $420.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Lyra Therapeutics reported Q1 EPS of $(0.35), missing estimates by 34.62% but improved from last year's $(0.44). Sales of $532K exceeded estimates by 26.67% and grew 29.76% year-over-year.
April 30, 2024 | 8:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lyra Therapeutics missed Q1 EPS estimates but showed significant sales growth, beating expectations.
While the EPS miss might concern some investors, the significant beat on sales and year-over-year growth could offset negative sentiment. The mixed results present a neutral short-term outlook as investors weigh the implications of revenue growth against earnings misses.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100